Aeterna Zentaris (AEZS) Competitors $4.10 +0.26 (+6.77%) As of 07/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsTrendsBuy This Stock AEZS vs. LSTA, CARA, TENX, CYTH, BCAB, CALC, GBIO, FBLG, FGEN, and NNVCShould you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Lisata Therapeutics (LSTA), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Cyclo Therapeutics (CYTH), BioAtla (BCAB), CalciMedica (CALC), Generation Bio (GBIO), FibroBiologics (FBLG), FibroGen (FGEN), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical products" industry. Aeterna Zentaris vs. Its Competitors Lisata Therapeutics Cara Therapeutics Tenax Therapeutics Cyclo Therapeutics BioAtla CalciMedica Generation Bio FibroBiologics FibroGen NanoViricides Lisata Therapeutics (NASDAQ:LSTA) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings. Which has higher valuation and earnings, LSTA or AEZS? Aeterna Zentaris has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLisata Therapeutics$1M21.81-$19.99M-$2.30-1.10Aeterna Zentaris$2.37M3.10-$16.55M-$14.86-0.28 Is LSTA or AEZS more profitable? Lisata Therapeutics has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -760.32%. Lisata Therapeutics' return on equity of -61.37% beat Aeterna Zentaris' return on equity.Company Net Margins Return on Equity Return on Assets Lisata TherapeuticsN/A -61.37% -53.35% Aeterna Zentaris -760.32%-83.45%-45.76% Which has more volatility & risk, LSTA or AEZS? Lisata Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Do analysts prefer LSTA or AEZS? Lisata Therapeutics presently has a consensus target price of $23.50, suggesting a potential upside of 828.85%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Lisata Therapeutics is more favorable than Aeterna Zentaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Aeterna Zentaris 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in LSTA or AEZS? 8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by insiders. Comparatively, 0.1% of Aeterna Zentaris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to LSTA or AEZS? In the previous week, Lisata Therapeutics had 10 more articles in the media than Aeterna Zentaris. MarketBeat recorded 10 mentions for Lisata Therapeutics and 0 mentions for Aeterna Zentaris. Lisata Therapeutics' average media sentiment score of 0.75 beat Aeterna Zentaris' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Lisata Therapeutics Positive Aeterna Zentaris Neutral SummaryLisata Therapeutics beats Aeterna Zentaris on 11 of the 15 factors compared between the two stocks. Get Aeterna Zentaris News Delivered to You Automatically Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEZS vs. The Competition Export to ExcelMetricAeterna ZentarisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.35M$816.22M$5.54B$9.41BDividend YieldN/A4.84%3.75%4.03%P/E Ratio-0.281.2021.0120.09Price / Sales3.1025.49433.8199.01Price / CashN/A19.5636.1658.27Price / Book0.276.878.125.65Net Income-$16.55M-$4.17M$3.25B$257.91M7 Day Performance16.81%0.03%0.97%2.09%1 Month Performance14.91%2.12%7.36%11.13%1 Year Performance-31.36%2.14%31.31%18.40% Aeterna Zentaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AEZSAeterna ZentarisN/A$4.10+6.8%N/A-40.2%$7.35M$2.37M-0.2820Gap DownHigh Trading VolumeLSTALisata Therapeutics2.8127 of 5 stars$2.84+14.3%$15.00+429.1%-34.2%$24.43M$1M-1.2330News CoveragePositive NewsAnalyst ForecastGap DownCARACara Therapeutics0.2147 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumeTENXTenax Therapeutics1.5517 of 5 stars$5.80+0.9%$17.50+201.7%+70.9%$24.06MN/A-2.349CYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809BCABBioAtla2.2325 of 5 stars$0.40+2.8%$5.00+1,159.4%-79.5%$23.19M$11M-0.3360News CoverageCALCCalciMedica3.1593 of 5 stars$1.65+2.2%$18.00+994.2%-45.2%$22.98MN/A-1.0530News CoveragePositive NewsGap UpGBIOGeneration Bio3.862 of 5 stars$0.34+3.6%$7.33+2,044.2%-82.8%$22.93M$19.89M-0.32150News CoverageAnalyst ForecastStock SplitGap DownFBLGFibroBiologics3.5536 of 5 stars$0.59-1.8%$13.00+2,088.6%-87.2%$22.73MN/A-2.8310FGENFibroGen4.7015 of 5 stars$5.58+3.9%$250.00+4,380.3%-69.8%$22.54M$29.62M-2.23570Positive NewsNNVCNanoViricides0.3733 of 5 stars$1.39+0.7%N/A-27.4%$22.37MN/A-1.9320Positive News Related Companies and Tools Related Companies LSTA Alternatives CARA Alternatives TENX Alternatives CYTH Alternatives BCAB Alternatives CALC Alternatives GBIO Alternatives FBLG Alternatives FGEN Alternatives NNVC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AEZS) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
